3-MeO-PCP (3-methoxyphencyclidine) is a synthetic dissociative of the arylcyclohexylamine class that occupies a unique and contested position in the research chemical landscape: widely regarded as one of the most euphoric dissociatives ever made, and simultaneously one of the most dangerous. A methoxylated analog of PCP with the phenyl ring substituted at the 3-position, it entered the research chemical market in the early 2010s and quickly accumulated a community reputation that no other novel dissociative quite matches -- not for its potency or its visuals, but for its insidious capacity to produce mania that feels indistinguishable from lucidity.
The pharmacological signature of 3-MeO-PCP is a stimulant-dissociative hybrid. At low doses (2-5 mg insufflated), it functions more like a stimulant than a classical dissociative: clean energy, sharpened focus, elevated mood, enhanced social fluency, and a sense of physical capability that has made it popular for exercise, creative work, and social situations among experienced users. This functional, almost nootropic character at threshold doses is what draws people in. But 3-MeO-PCP has a dose-response curve that is legendarily steep and non-linear. The distance between "clear-headed euphoric stimulation" and "full-blown manic psychosis" can be as little as 10-15 milligrams, and the transition happens without a perceptual warning track. Users do not feel themselves becoming manic. They feel themselves becoming brilliant.
This is the defining hazard, and it is why the harm reduction community has generated more safety discussion around 3-MeO-PCP than around almost any other research chemical. The accumulated wisdom of years of community experience can be distilled into a single observation: 3-MeO-PCP's mania is subjectively invisible. People in the grip of 3-MeO-PCP mania consistently report feeling exceptionally clear-headed, capable, and in control while exhibiting behavior that is objectively disinhibited, grandiose, and impaired. First-person retrospective accounts -- "I thought I was having the most profound experience of my life, and my roommate says I was pacing in circles talking to the wall for three hours" -- are a recurring feature of community literature. Multiple hospitalizations and at least several deaths have been attributed to 3-MeO-PCP, primarily through behavioral consequences of manic episodes rather than direct pharmacological toxicity.
Despite these risks, 3-MeO-PCP has maintained consistent interest because for users who can navigate its narrow therapeutic window -- low doses, infrequent use, strict no-redosing discipline, and ideally the presence of a sober observer -- it reportedly offers a dissociative experience with a warmth, euphoria, and cognitive stimulation that no other substance in the class replicates. The harm reduction community broadly classifies it among the higher-risk common dissociatives, and treats it with a respect that borders on wariness.
Safety at a Glance
High Risk- The Mania Trap: Read This First
- Dosing: Conservative and Precise
- Toxicity: Mania and Psychosis: The Primary Toxicity The most extensively documented and most clinically significant toxicity of...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: 3-MeO-PCP overdose can present across a spectrum from behavioral emergency (mania/psychosis requi...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
smoked
Duration
insufflated
Total: 3 hrs – 5 hrsoral
Total: 4 hrs – 8 hrssmoked
Total: 45 min – 2 hrsHow It Feels
It starts with a gathering sense of energy that is difficult to locate -- not in the chest, not in the limbs, but somewhere behind and above the eyes, as though a generator has been switched on in a room of the mind you do not normally visit. Within twenty minutes you feel it spreading: a clean, almost clinical stimulation that straightens the spine and sharpens the gaze. The body begins to feel peculiar -- simultaneously present and absent, as though you are wearing yourself like a suit of armor that has become strangely weightless.
The come-up is where 3-MeO-PCP begins to distinguish itself from every other dissociative in the pharmacopoeia. The stimulation intensifies into something that feels less like energy and more like certainty. You do not merely think -- you know. Ideas arrive with the force of revelation, each one accompanied by a somatic flush of conviction that runs through the body like a wave. You begin to speak faster, more fluently, more confidently. The dissociation is present but secondary, a background hum of detachment that allows you to observe your own acceleration with a strange, clinical interest.
At the peak, the world reorganizes itself around you. You are not merely in the room -- you are the organizing principle of the room. There is a grandiosity here that is qualitatively different from the inflated confidence of stimulants: it is metaphysical, a sense that you have pierced some veil and are seeing the machinery of reality itself. Sound becomes extraordinarily vivid; music is not merely heard but understood at the level of its mathematical structure. The body is profoundly numb and curiously powerful -- you feel capable of extraordinary physical feats, though your coordination may not agree. At higher doses, this certainty can detach entirely from reality, spiraling into delusion and confabulation, the mind constructing elaborate narratives that feel more real than the room around you.
And here is the trap -- the feature that makes 3-MeO-PCP categorically more dangerous than other dissociatives at equivalent doses. The mania does not announce itself. There is no moment where the experience shifts from insight to delusion, no perceptual flag that says "you are now impaired." The grandiosity feels earned, the certainty feels genuine, and the behavioral disinhibition feels like liberation. First-person retrospective accounts are remarkably consistent: "I felt perfectly lucid. I was absolutely certain I was thinking more clearly than I ever had. My sitter told me I had been pacing and monologuing for two hours about things that made no sense." This is the insidious quality that the community warns about, and it is real. You cannot trust your own judgment of your judgment while on 3-MeO-PCP. That sentence sounds paradoxical but it is the most important thing to understand about this compound.
The descent is long and can be deeply uncomfortable. The stimulation persists for hours after the dissociative peak has passed, leaving you in a state of wired lucidity that resists sleep and invites obsessive thinking. The grandiosity fades, often replaced by a flat, slightly paranoid wakefulness. Baseline may take twelve hours or more to return. The afterglow is variable -- some report a pleasant mental clarity lasting days, while others describe a brittle, depleted feeling, as though the mind has been run too hard and is now coasting on fumes.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(23)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite enhancement— A distinct increase in hunger and desire for food, often accompanied by enhanced enjoyment of taste ...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Nausea suppression— Nausea suppression is the pharmacological reduction or elimination of nausea and the urge to vomit, ...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vibrating vision— Vibrating vision is the subjective experience of the visual field rapidly oscillating or shaking due...
Tactile(2)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(10)
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(23)
- Addiction suppression— Addiction suppression is the experience of a marked decrease in or complete cessation of the craving...
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(5)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
- Auditory suppression— A dampening of auditory perception in which sounds become muffled, distant, and reduced in both volu...
Multi-sensory(2)
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
Pharmacology
NMDA Receptor Antagonism
3-MeO-PCP's core mechanism is non-competitive NMDA receptor antagonism, shared with all arylcyclohexylamines. It binds to the PCP site within the NMDA receptor ion channel with a Ki of 20 nM -- higher affinity than PCP itself, making it one of the most potent NMDA antagonists in the arylcyclohexylamine class. The methoxy substitution at the 3-position of the phenyl ring shifts the pharmacological profile relative to PCP: longer duration, more stimulant character, and a dissociative quality that is described as "cleaner" and less sedating than PCP at equivalent NMDA-blocking doses. Like PCP and unlike ketamine, 3-MeO-PCP also shows high affinity for the PCP2 glutamate receptor, a relatively unstudied site whose functional significance remains unclear.
Sigma Receptor Activity
3-MeO-PCP has potent sigma-1 receptor affinity (Ki = 42 nM), placing it among the highest-affinity sigma ligands in the arylcyclohexylamine class. Sigma-1 receptor agonism is associated with stimulant effects, mood elevation, antidepressant-like activity, and at higher activation levels, psychotomimetic effects including the grandiosity, racing thoughts, and reality distortion characteristic of mania. The sigma system is likely a major contributor to 3-MeO-PCP's distinctively stimulant character and its high propensity for manic states -- separating it from more purely NMDA-mediated dissociatives like ketamine that have minimal sigma activity.
Dopaminergic Involvement
The extent of 3-MeO-PCP's dopaminergic activity has been debated. Early characterizations suggested opioid and dopaminergic activity, but binding data shows minimal affinity for the mu-opioid receptor and dopamine transporter. However, the compound's behavioral profile -- euphoria, stimulation, compulsive redosing, mania -- is consistent with downstream dopaminergic effects, possibly mediated indirectly through NMDA-dependent modulation of mesolimbic dopamine pathways or through sigma receptor-mediated dopamine release. Whether the mechanism is direct or indirect, the functional result is clear: 3-MeO-PCP engages reward and activation circuitry in a way that most other NMDA antagonists do not.
Serotonin Transporter Activity
3-MeO-PCP shows moderate affinity for the serotonin transporter (Ki = 216 nM), indicating mild serotonin reuptake inhibition. This contributes to its mood-elevating properties and creates interaction risks with other serotonergic substances (particularly MDMA and MAOIs), though the serotonergic component is less dominant than in DXM.
Dose-Response Characteristics
The dose-response curve of 3-MeO-PCP is the single most important pharmacological fact for harm reduction purposes. The transition from stimulant-dissociative (functional, euphoric, cognitively enhancing) to manic (grandiose, disinhibited, judgment-impaired) to psychotic (delusional, hallucinatory, reality-divorced) occurs across a remarkably narrow dose range. Community consensus places the inflection point somewhere around 15-20 mg for most users by the insufflated route, but individual variation is large and tolerance status dramatically shifts the curve. This steep non-linearity, combined with the subjective invisibility of the manic transition, is the core pharmacological hazard.
Pharmacokinetics
Active effects last 4-6 hours or more, with an extended aftereffect period that can persist for 12-24 hours. The long duration -- substantially longer than ketamine and comparable to PCP -- is a contributing factor to accidental overdose, as users who redose before full effects manifest frequently overshoot their intended dose. The arylcyclohexylamine scaffold is lipophilic, contributing to tissue accumulation and extended clearance times with repeated dosing.
Detection Methods
Standard Drug Panel Inclusion
3-MeO-PCP has the potential to trigger a positive result on standard PCP immunoassay screens due to its structural similarity to phencyclidine. However, cross-reactivity is variable and depends on the specific immunoassay platform used. Some assays detect 3-MeO-PCP reliably, while others show reduced or negligible cross-reactivity. A negative PCP screen does not rule out 3-MeO-PCP use, and a positive PCP screen in a user claiming only 3-MeO-PCP use cannot confirm PCP itself without further analysis.
Urine Detection
3-MeO-PCP is detectable in urine for approximately 3 to 7 days after a single dose. The compound is metabolized by hepatic O-demethylation to 3-HO-PCP and by hydroxylation to other metabolites. Both the parent compound and its metabolites may be present in urine. The lipophilic nature of arylcyclohexylamine dissociatives contributes to extended detection windows. LC-MS/MS methods targeting both 3-MeO-PCP and its demethylated metabolite 3-HO-PCP are required for definitive detection.
Blood and Serum Detection
Blood detection windows are 1 to 3 days. Active blood concentrations are in the low to moderate nanogram-per-milliliter range. Pharmacokinetic parameters have been partially characterized through forensic case reports and animal studies, but systematic human pharmacokinetic data is limited.
Hair Follicle Detection
Hair analysis for 3-MeO-PCP is feasible using LC-MS/MS methods, with detection windows up to 90 days. The basic, lipophilic nature of the compound favors incorporation into the hair matrix, similar to PCP.
Confirmatory Methods
LC-MS/MS is the preferred confirmatory method. The analytical panel should include both 3-MeO-PCP and 3-HO-PCP to capture the full metabolic profile. GC-MS can also identify 3-MeO-PCP with appropriate reference standards. The compound must be explicitly included in the analytical panel, as standard PCP confirmation methods may not detect it.
Reagent Testing
The Marquis reagent produces no reaction or a faint yellow with 3-MeO-PCP. The Mandelin reagent may yield an orange to brown color. The Mecke reagent produces a green to black reaction. Reagent testing can help rule out substitution with other drug classes but cannot definitively identify 3-MeO-PCP among PCP analogues.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Synthesis and Pharmacological Characterization
3-MeO-PCP was first synthesized during the systematic structure-activity relationship (SAR) exploration of phencyclidine analogs that characterized mid-to-late 20th century dissociative pharmacology research. Medicinal chemists systematically varied the PCP scaffold -- substituting the phenyl ring, modifying the piperidine nitrogen, altering the cyclohexane -- to map how structural changes affected NMDA receptor affinity, duration, and behavioral profile. The methoxy substitution at the 3-position of the phenyl ring was found to produce a compound with higher NMDA receptor affinity than PCP itself and a shifted effect profile: more stimulant, less sedating, longer duration. The compound was characterized pharmacologically in research publications but attracted no clinical development interest.
Emergence as a Research Chemical (2011-2013)
3-MeO-PCP first appeared on the research chemical market in 2011, offered by online vendors alongside the burgeoning catalog of novel dissociatives that included MXE, 3-MeO-PCE, and methoxetamine. Early community reports on platforms including Bluelight's "Big and Dandy" threads and Reddit's r/researchchemicals emphasized its unusual stimulant-dissociative character -- a profile that was genuinely novel in the available dissociative landscape, which was then dominated by ketamine-like and MXE-like compounds. The early enthusiasm was real: users described a dissociative that was functional, euphoric, and cognitively enhancing in ways that ketamine and MXE were not.
The Mania Reckoning (2014-2016)
By 2014-2015, the community data had accumulated enough to paint a more complex picture. Reports of manic episodes, behavioral dysregulation, and hospitalizations appeared with increasing frequency. Community discussions shifted from "this is an amazing functional dissociative" to "this is an amazing functional dissociative that can destroy your life if you do not treat it with extreme caution." Warning threads about contaminated batches with unusually high potency, first-person accounts of recognized-in-hindsight mania, and collectively developed dosing frameworks all emerged during this period. This evolution represents genuine community safety work -- the accumulation and synthesis of adverse event data in real time, performed by the user community in the absence of any formal pharmacovigilance system.
Ongoing Status and Legal Evolution
3-MeO-PCP has been explicitly scheduled in multiple jurisdictions. In the UK it was classified as a Class B drug (later effectively covered by the Psychoactive Substances Act). Germany added it to Anlage II of the BtMG in 2015. Denmark, Brazil, Switzerland, the Czech Republic, the Netherlands, and Italy have all scheduled it. In the United States, it is not explicitly scheduled but is likely prosecutable under the Federal Analogue Act due to its structural and pharmacological relationship to PCP. Despite increasing legal restrictions, 3-MeO-PCP remains available through international research chemical vendors and continues to generate community discussion, experience reports, and harm reduction guidance.
Harm Reduction
The Mania Trap: Read This First
3-MeO-PCP's primary danger is not respiratory depression, not seizures, and not cardiac events. It is mania that feels like clarity. Before using this substance, read community accounts of 3-MeO-PCP mania. Read the retrospective reports where users describe feeling perfectly lucid while behaving in ways they later found horrifying. Understand that when you are manic on 3-MeO-PCP, you will not believe you are manic. This is not a theoretical risk -- it is the most frequently reported serious adverse effect of this compound.
Dosing: Conservative and Precise
The dose-response curve is steep and unforgiving. A milligram scale is mandatory. Volumetric dosing is strongly recommended given that most standard scales are unreliable below 10-15 mg.
- Insufflated: start at 2-5 mg. Common dose: 5-15 mg. High dose: 15-25 mg. Above 25 mg: territory where mania and psychosis become likely for most users
- Oral: start at 3-7 mg. Onset is slower (45-90 minutes), which increases redosing temptation -- resist it
- Do not redose during the experience. The long duration (4-6+ hours active, 12+ hours to baseline) means that redosing before full effects manifest is one of the most common routes to overdose-equivalent experiences. Set your dose, take it, and accept that dose as your experience for the day
Designated Sober Observer
This is not a "trip sitter" in the psychedelic sense -- it is a behavioral monitor. The ideal observer is someone who knows what 3-MeO-PCP mania looks like, who has been explicitly authorized by you in advance to say "you are behaving in a concerning way and I think you should sit down," and whose judgment you have committed to trusting over your own. This sounds dramatic. It is proportionate to the risk.
Frequency: Less Is Safer
The risk of mania escalates with frequency of use. Community harm reduction frameworks recommend using no more than once every 2-4 weeks, with many experienced users suggesting once per month or less. Consecutive-day use dramatically increases the probability of manic episodes, compulsive redosing, and the gradual normalization of hypomanic behavior that characterizes the slide into dependence.
Absolute Contraindications
- Bipolar disorder, especially bipolar I with manic episodes -- 3-MeO-PCP has a specific and documented propensity to trigger full manic episodes in susceptible individuals. This is a hard contraindication, not a caution
- Family history of psychotic disorders -- the psychotomimetic potential is high enough to warrant avoidance
- Current use of stimulants -- amphetamines, cocaine, MDMA combined with 3-MeO-PCP dramatically amplifies mania, cardiovascular stress, and psychosis risk
- MAOIs -- the serotonergic and dopaminergic activity creates potentially dangerous interactions
Other Dangerous Combinations
- Cannabis -- frequently reported to intensify manic and psychotic features. Many of the worst community-reported 3-MeO-PCP experiences involve cannabis co-use
- Other dissociatives -- additive NMDA blockade with unpredictable psychotomimetic effects
- Alcohol -- potentiates disinhibition and impairs judgment further
- Buprenorphine/Suboxone -- community reports describe complex and sometimes dangerous interactions
Microdosing: Not as Safe as It Sounds
Community accounts of extended daily microdosing (including a documented 7+ month daily use case) exist but should not be taken as evidence of safety. Regular low-dose use accumulates tolerance, dependence risk, potential bladder toxicity, and a gradual shift in behavioral baseline that may be imperceptible to the user. The mania-invisibility problem applies at every dose level -- chronic low-dose mania is even harder to detect than acute high-dose mania.
Toxicity & Safety
Mania and Psychosis: The Primary Toxicity
The most extensively documented and most clinically significant toxicity of 3-MeO-PCP is not a classical dose-dependent organ toxicity but a behavioral syndrome: mania progressing to psychosis. This distinguishes it from most other dissociatives, where the primary acute risks are respiratory depression, cardiovascular stress, or trauma from motor impairment.
3-MeO-PCP mania is characterized by grandiosity, pressured speech, disinhibited behavior, dramatically reduced need for sleep, racing thoughts, and a subjective experience of exceptional clarity and capability. The critical feature is that this state is experienced as profoundly positive by the user -- they feel better, not worse -- while their behavior becomes objectively dysregulated and sometimes dangerous. Community reports range from mild euphoric overconfidence to full manic episodes requiring psychiatric hospitalization with antipsychotic treatment.
At higher doses, frank psychosis -- paranoid delusions, hallucinations, disorganized thinking, complete loss of reality testing -- is documented in multiple community reports and case literature. In some cases, psychotic episodes have persisted for days to over a week after last use.
Cardiovascular Effects
The stimulant character of 3-MeO-PCP elevates heart rate, blood pressure, and body temperature. In healthy individuals at moderate doses, these effects are generally manageable. However, cardiovascular risk escalates significantly with higher doses, combination with stimulant drugs, pre-existing cardiovascular conditions, or sustained physical exertion during intoxication (which the stimulant effects may encourage).
Accident and Behavioral Risk
The stimulant-dissociative combination is uniquely hazardous: it impairs coordination and judgment while simultaneously producing a subjective sense of enhanced capability. Users are simultaneously less capable and more confident -- a combination that invites risk-taking behavior, accidents, and decisions that sober retrospection reveals as deeply impaired. Community reports include near-accidents during driving (undertaken in the sincere belief that the user was sober), interpersonal conflicts arising from manic disinhibition, and physical injuries from activities attempted with misplaced confidence.
Bladder and Urinary Tract Toxicity
Chronic use of 3-MeO-PCP produces bladder and urinary tract symptoms comparable to (though generally less severe than) ketamine-induced cystitis: urinary frequency, urgency, pelvic pain, and in severe cases hematuria and incontinence. The lower severity relative to ketamine is likely attributable to 3-MeO-PCP's higher potency per milligram, meaning less total drug passes through the urinary system. These effects are cumulative and worsen with both dose and frequency. Notably, concurrent use of other stimulant drugs (even at separate times) has been reported to compound urinary tract effects.
Supply Chain Risk
As an unregulated research chemical, 3-MeO-PCP carries inherent supply chain uncertainty. Community warnings about reportedly contaminated batches with unusual potency appear periodically. The combination of an already-steep dose-response curve with unknown purity creates a compounded risk that is difficult to mitigate without analytical testing. Reagent testing can exclude gross substitution with other drug classes but cannot confirm identity or purity among PCP analogs.
Drug Interactions
- Stimulants (amphetamines, cocaine, MDMA) -- dramatically amplifies cardiovascular stress, mania, and psychosis risk. Strongly contraindicated
- Cannabis -- frequently and specifically reported to intensify manic and psychotic features. Many of the worst documented 3-MeO-PCP experiences involve cannabis
- MAOIs -- potentially dangerous given serotonergic and dopaminergic activity
- Buprenorphine/Suboxone -- community reports describe complex and sometimes alarming interactions that are not well characterized
- Other dissociatives -- additive NMDA blockade, unpredictable psychotomimetic synergy
- Alcohol -- potentiates disinhibition, ataxia, and aspiration risk
Addiction Potential
3-MeO-PCP produces dependence with chronic use and carries a notably high potential for abuse relative to other dissociatives. Several features of its pharmacological profile converge to create addiction risk that exceeds ketamine, MXE, and most other arylcyclohexylamines. The euphoric and stimulant effects at low doses provide strong positive reinforcement. The anxiolytic and confidence-enhancing properties provide negative reinforcement (relief from anxiety and self-doubt). The subjective feeling of enhanced cognition creates a rationalization pathway -- users convince themselves that they are "better" on the drug, making continued use feel justified rather than compulsive. And the insidious quality of hypomanic states means that the behavioral escalation characteristic of developing dependence may be invisible to the user, who genuinely experiences themselves as functioning better, not worse. Compulsive redosing is a frequently reported feature, particularly via routes with rapid onset (insufflation, vaporization). The combination of euphoria, stimulation, and the long tail of residual effects (which invite "just one more" when the peak fades but the user is still awake and stimulated) creates a redosing pattern that can easily lead to dose escalation within a single session. Tolerance develops with repeated use and follows the typical dissociative pattern: 3-7 days to half-baseline, 1-2 weeks to full baseline recovery. Cross-tolerance exists with all dissociatives. Multiple community reports describe serious psychological dependence developing over weeks to months of regular use, with craving, withdrawal dysphoria, and difficulty discontinuing. The withdrawal syndrome includes depression, anhedonia, irritability, cognitive impairment, and intense craving for the euphoric and stimulating effects. Community accounts of extended daily use -- including one detailed account of 7+ months of daily microdosing for ADHD and depression management -- provide real-world data on dependence trajectories. These accounts consistently describe a pattern of gradual dose escalation, increasing normalization of the intoxicated state, difficulty recognizing the cumulative behavioral changes, and eventual recognition (often prompted by external feedback from friends or family) that what felt like self-medication had become dependence. The harm reduction community rates 3-MeO-PCP among the more dependency-prone dissociatives and recommends strict frequency limits (no more than once per month) as a primary risk mitigation strategy.
Overdose Information
3-MeO-PCP overdose can present across a spectrum from behavioral emergency (mania/psychosis requiring intervention) to life-threatening medical crisis, depending on dose, route, combination substances, and individual factors.
Recognizing Overdose
Behavioral signs (mania/psychosis):
- Rapid, pressured speech about grandiose or delusional topics
- Inability to sit still, pacing, repetitive movements
- Apparent unawareness of bizarre or dangerous behavior
- Insistence that they are "fine" or "thinking more clearly than ever" while behaving erratically
- Aggression or confrontational behavior (less common than with PCP but documented)
Medical signs (requiring emergency response):
- Severe nystagmus (rapid involuntary eye movements)
- Complete unresponsiveness
- Vomiting (aspiration risk, especially if unconscious)
- Seizures
- Severely depressed or absent breathing
- Very rapid heartbeat or reported chest pain
- Extremely elevated body temperature
- Muscle rigidity
Emergency Response
For manic/psychotic presentation without medical emergency: Move to a quiet, low-stimulation environment. Do not argue with delusions or attempt to "talk them down" through logic. Speak calmly, in short sentences. If the person has a pre-arranged sober observer, this is the moment that arrangement pays for itself. Call 911 if the person is a danger to themselves or others, or if the behavioral state does not begin to de-escalate within a reasonable timeframe
For medical emergency signs: Call 911 immediately. Place unconscious person in recovery position (on their side) to prevent aspiration. If not breathing, begin CPR. Monitor body temperature. Be completely honest with emergency responders about what was consumed -- "a research chemical dissociative called 3-MeO-PCP, a PCP analog" gives them the information they need for treatment decisions
Critical note on restraint: Do not attempt to physically restrain the person unless they are in immediate danger of severe injury. Physical restraint of a stimulated, dissociated individual risks injury to both parties and can worsen potential rhabdomyolysis
Hospital Management
Emergency departments will typically manage 3-MeO-PCP toxicity similarly to PCP: benzodiazepines for agitation and seizures, active cooling for hyperthermia, IV fluids (especially if rhabdomyolysis is suspected), and monitoring for cardiovascular complications. Antipsychotics (typically haloperidol) may be used for severe psychotic presentations. Providing the specific substance name helps medical staff, but if unknown, "PCP analog" or "research chemical dissociative" gives them an appropriate treatment framework.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Austria:** 3-MeO-PCP is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil:** As of May 17, 2018, 3-MeO-PCP has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.
Germany:** On November 21, 2015, 3-MeO-PCP was added to "Anlage II" of the controlled substance act ("BtMG"), making it illegal to produce, sell or possess.
Denmark:** As of August 25th, 2015, all MeO-PCP isomers (including 3-MeO-PCP) were added to the list of illegal substances in Denmark.
Sweden:** Sweden's public health agency suggested classifying 3-MeO-PCP as a hazardous substance on November 10, 2014.
Switzerland:** 3-MeO-PCP is a controlled substance specifically named under Verzeichnis E.
Turkey:** 3-MeO-PCP is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** 3-MeO-PCP is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
United States:** 3-MeO-PCP is not a controlled substance in the United States but possession or distribution of 3-MeO-PCP for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to PCP.
Czech Republic: 3-MeO-PCP is a Schedule I controlled substance.
The Netherlands: 3-MeO-PCP is a Schedule I controlled substance.
Italy:** 3-MeO-PCP is a Schedule I controlled substance.
Responsible use
Research chemical
Dissociative
Arylcyclohexylamine
PCP
3-MeO-PCP (Wikipedia)
3-MeO-PCP (Erowid Vault)
3-MeO-PCP (Isomer Design)
Discussion and Media
The Big & Dandy 3-MeO-PCP Thread (Bluelight)
Interview with a Ketamine Chemist (VICE)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
Experience Reports (1)
Tips (10)
There have been reports of potentially lethal batches of 3-MeO-PCP circulating. Always allergy test with a tiny amount first, and use a milligram scale. Even slight overdoses of this substance can cause severe mania, psychosis, and medical emergencies.
3-MeO-PCP mania is not euphoric fun — it can manifest as paranoia, grandiose delusions, aggression, and complete loss of judgment. Many users describe stripping naked, confronting strangers, or destroying property while believing they were acting normally.
Never exceed 10mg without extensive prior experience. At 15mg insufflated, users report losing hours of memory. At 50mg, cardiac emergency symptoms appear. The dose-response curve is extremely steep — treat every milligram as significant.
The moreish quality of many dissociatives including 3-MeO-PCP makes compulsive redosing common. Pre-measure your intended dose and put the rest away. A timed lockbox can help prevent impulsive additional doses.
3-MeO-PCP combined with Suboxone or other opioid medications is unpredictable and potentially dangerous. The substance may interact with opioid receptors. Do not combine without medical guidance.
Tolerance to 3-MeO-PCP builds with regular use. Taking breaks of at least 1-2 weeks between sessions helps prevent tolerance escalation and reduces the risk of bladder and cognitive damage from frequent use.
Community Discussions (12)
See Also
Similar by Effects
Same Class
References (3)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- 3-MeO-PCP - TripSit Factsheet
TripSit factsheet for 3-MeO-PCP
tripsit - 3-MeO-PCP - Wikipedia
Wikipedia article on 3-MeO-PCP
wikipedia